ClinicalTrials.gg
SuspendedNCT04589065Updated Sep 27, 2024

SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device)

An interventional study of Selective Cytopheretic Device in Heart Failure, Chronic Systolic Heart Failure and Renal Failure, sponsored by Lenar Yessayan. Suspended at 1 site in United States. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-09-27.

Primary conditionCardio-Renal SyndromeRegistry: Heart FailureReclassifiedWhy we changed it
Registry
Heart Failure — the first condition term the registry derived for this study.
ClinicalTrials.gg
Cardio-Renal Syndrome
Why
  1. The study's listed conditions name Cardio-Renal Syndrome, a narrower term within Heart Failure.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Lenar Yessayan · Not applicable, Interventional, and Treatment

How we know

Why this study was suspended
Recruitment on hold pending amendment approval.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Cardio-Renal Syndrome with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Cardio-Renal Syndrome · United States.

Planned enrollment
12th of 16
10 · median 20
Started
2025
with 1 other
No phase
6 of 18
3 open now
Registered
15th of 18
by date
Lead sponsor
1 of 18
Lenar Yessayan

Among the 18 studies in Cardio-Renal Syndrome with a site in United States, this one is the 12th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 with no phase, and was the 15th registered.

Cardio-Renal Syndrome

85 studies on the registry are indexed under Cardio-Renal Syndrome; 20 are open to participants now.

Browse Cardio-Renal Syndrome studies →

Open to participants now

3 of the 18 studies in Cardio-Renal Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Cardio-Renal Syndrome studies recruiting now, 9 (75%) set no upper age limit and 2 (17%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 21 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Cardio-Renal Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to see if a new device (SCD) is safe and if it can reduce damage to the kidney enough to allow medications to work to improve heart and kidney function for use in patients that have moderate to severe heart failure and is at least in part due to heart failure and it not responding to standard medical therapy. The SCD is a cartridge used with a commercial hemodialysis unit.

Participants will be enrolled in the clinical trial once eligibility is confirmed. In addition to clinical assessments and laboratory testing participants will have surface echocardiograms during the trial. The SCD treatment will take place for 4 hours on day 1, 3, and 5 while on hemodialysis.

03

Conditions studied

  • Heart Failure
  • Chronic Systolic Heart Failure
  • Renal Failure
  • Cardiorenal Syndrome

Browse trials for

Keywords

  • Hospitalized
04

In context

Cardio-Renal Syndrome Reclassified

85 studies on the registry are indexed under Cardio-Renal Syndrome; 20 are open to participants now.

This study's planned enrollment of 10 is below the median of 50 across 55 interventional studies indexed under Cardio-Renal Syndrome.

Browse Cardio-Renal Syndrome studies →

Lead sponsor

Lenar Yessayan is the lead sponsor of 2 studies on the registry; none are open to participants now.

Compared within Cardio-Renal Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Failure. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary hospitalization for acute decompensated chronic systolic heart failure as defined:

    • ≤35% as confirmed by baseline imaging procedure.
    • (NYHA) class III or IV chronic (≤ 90 days) systolic heart failure, with failure to respond to optimal medical therapy (beta blocker, Angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blockers (ARB) or valsartan/sacubitril, aldosterone antagonist, unless not tolerated or , and loop diuretic, as needed) for 45 of the last 60 days.
  • Baseline Estimated (eGFR)** ≥ 40 ml/min/1.73 m2 (baseline defined as the highest known eGFR within 90 days of study enrollment)
  • Worsening renal failure (WRF), defined for the purposes of this study as increase serum creatinine ≥ 0.5 mg/dL from baseline (baseline defined as the lowest known serum creatinine within 90 days of study enrollment)
  • Cardiorenal syndrome is the most likely explanation for WRF
  • Persistent signs and /or symptoms of congestion (peripheral edema, dyspnea, pulmonary rales, neck vein distension) despite optimal medical therapy including intravenous diuretic therapy and an estimated need for greater than 5 kg. of fluid removal. For the purposes of this study, optimal intravenous diuretic therapy is defined as:

    • Furosemide equivalent total daily dose of 240 mg (furosemide 40mg=1mg bumetanide)
    • Furosemide equivalent dose given either as a single or multiple intravenous bolus or continuous infusion
    • A furosemide equivalent total daily dose \<240 mg if the dose has resulted in >3000 ml urine output/24 hours

Exclusion criteria

Exclusion Criteria:

  • Prior sensitivity to dialysis device components
  • Individual with known to citrate
  • Bacteremia or possible infection, as evidence by fever, white blood cell count > 10,000/microliter, or any other signs of acute or chronic infection, and any patient receiving antibiotic or antiviral therapy.
  • Active requiring chemotherapy, biological therapy or radiation therapy.
  • The use of intravenous iodinated contrast agent within the prior 72 hours or the anticipated use of such an agent during SCD therapy.
  • Need for intravenous vasopressor (i.e., phenylephrine, vasopressin), intravenous. vasoconstricting inotrope (i.e., norepinephrine or epinephrine) or dopamine > 3 mcg/kg/min. (Note: use of vasodilating inotropes [i.e., dobutamine and milrinone] or dopamine at ≤ 3 mcg/kg/min will not preclude study inclusion).
  • Persistent systolic blood pressure (SBP) \< 80 mmHg.
  • White blood cell (WBC)\<4000/microliter.
  • \< 50,000/microliter.
  • Serum creatinine > 4 mg/dL or receiving dialysis / continuous renal replacement therapy (CRRT)
  • Acute coronary syndrome within the past month.
  • Women who are pregnant, breastfeeding a child, or trying to become pregnant.
  • Subject not able to sign .
  • Use of any other drug or device within the previous 30 days
  • Concurrent enrollment in another interventional clinical trial. Patients enrolled in clinical studies where only measurements and/or samples are taken (i.e., no test device or test drug used) are allowed to participate.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Selective Cytopheretic Device

    Device: Selective Cytopheretic Device

Interventions

  • DeviceSelective Cytopheretic Device

    SCD therapy will take place for 4 hours on day 1, 3, and 5 while on hemodialysis treatment. Participants will be continue to be followed until 30 days after the last SCD treatment.

07

What researchers measure

Primary outcomes

  1. Improvement in Cardiac Function - Left Ventricular Ejection Fraction

    This will be assessed by surface echocardiography.

    Time frame: up to 4 weeks following last SCD treatment

Secondary outcomes

  1. Improved renal function as measured by serum creatinine

    Time frame: up to 4 weeks following the last SCD therapy

  2. Improved renal function as measured by blood urea nitrogen (BUN)

    Time frame: up to 4 weeks following the last SCD therapy

08

Study locations

1 site
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Dec 2027, 27 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2020
First posted
Oct 19, 2020
StartEst.
Sep 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Sep 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04589065
Lead sponsor
Lenar Yessayan
Responsible party
Lenar Yessayan (Professor of Medicine, University of Michigan) — Sponsor-investigator
First posted
Oct 19, 2020
Start date
Sep 2025 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 27, 2024

Study contacts

Keith Aaronson, MD
principal investigator · University of Michigan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion